Tagged with R

Switzerland As global science faces mounting complexity, the Paul Scherrer Institute (PSI) stands out as a model of long-term vision, technical excellence, and interdisciplinary ambition. Director Christian Rüegg discusses how PSI is advancing the frontiers of oncology, neuroscience, energy, and AI – developing radiopharmaceuticals and imaging entire neural networks, to enabling…

Europe Writing in the June 2025 edition of DIA’s Global Forum Magazine, Finn McCartney, Maria Dutarte, Petra Adámková, and Paola Kruger from the European Patients’ Academy on Therapeutic Innovation (EUPATI) weigh in on how the patient voice is being incorporated into Joint Clinical Assessments (JCA) under the new EU Health Technology…

Organon With a uniquely positioned healthcare system and early access to innovation, Puerto Rico has become a proving ground for Organon’s regional ambitions in Latin America and the Caribbean. In a dialogue that spans market dynamics, regulatory complexity, and the evolving landscape of women’s health, Millie Rivera offers insight into how…

Denmark Jakob Nielsen, CEO of Healthcare Denmark, discusses how Denmark has strengthened its role in global health diplomacy and life sciences since 2021. Nielsen highlights the country’s focus on strategic international partnerships, digitalisation, and patient-centric healthcare reform, positioning Denmark as a transparent and collaborative partner in addressing shared healthcare challenges. What…

Puerto Rico Mary Carmen Zapata brings over 30 years of experience at PREPA into her historic role as the organisation’s first female CEO. Since taking office in January 2025, her top priority has been stabilising Puerto Rico’s strained electrical system by coordinating efforts between the public sector and private operators like LUMA and…

Denmark Already one of Europe’s top countries for clinical trials per capita, Denmark has further strengthened its position in recent years. The number of active trials in the country rose from 410 in 2022 to 450 in 2023, backed by increasing citizen participation and a healthcare ecosystem built on trusted health…

Puerto Rico Already a solid hub for biopharma manufacturing and logistics, Puerto Rico is moving to sharpen its position in the evolving US reshoring landscape and attract new investment. Under the banner “Made in Puerto Rico is Made in the USA,” Governor Jenniffer Gonzalez-Colon is promoting the island’s unique value as both…

Germany Once a little-known mRNA pioneer, BioNTech became a household name with its COVID-19 vaccine developed alongside Pfizer. But the German biotech is now pursuing an even bigger transformation — and China is at the heart of its strategy. Using vaccine proceeds to tap China’s booming life sciences ecosystem, BioNTech has…

Puerto Rico Felix and Manuel de la Cruz of M&N Electronics discuss the company’s evolution over the years and its commitment to becoming the leading provider of industrial equipment in Puerto Rico. They highlight the company’s focus on customer service, growth opportunities in the local pharmaceutical sector, and expansion into new markets,…

Puerto Rico Omar Muñiz, President of Share Tech, discusses the company’s remarkable growth over the past two decades and its strategic diversification beyond the healthcare and life sciences sectors. He highlights the firm’s evolution into construction, environmental services, and software development, while addressing challenges such as talent acquisition, infrastructure costs, and resilience…

Denmark Peter Jorgensen, Director of the Danish Generic and Biosimilar Medicines Industry Association, discusses Denmark’s robust framework for generics and biosimilars, offering insight into a system that has delivered high penetration, cost savings, and broad public trust. From legal structures and patient attitudes to incentives and hospital adoption, Jorgensen outlines why…

Switzerland Amid a crowded landscape of incremental innovation, Synendos Therapeutics stands out for its bold approach to neuropsychiatric drug development. Co-Founder and CEO Andrea Chicca shares how the company emerged from a translational research programme in Switzerland to pioneer a first-in-class therapeutic strategy targeting the endocannabinoid system, a master regulator of…